BTIG analyst Kaveri Pohlman upgraded Mersana (NASDAQ: MRSN) from Neutral to Buy with a price target of $6.00.The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Upgrades

Form 10-K Mersana Therapeutics, For: Dec 31February 28, 2024 8:49 AM Form POSASR Mersana Therapeutics, February 28, 2024 8:43 AM Mersana Therapeutics (MRSN) Tops Q4 EPS by 5cFebruary 28, 2024 7:18 AM Form 8-K Mersana Therapeutics, For: Feb 28February 28, 2024 7:08 AM Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 7:00 AM Mersana Therapeutics to Present at Upcoming Investor ConferencesFebruary 27, 2024 8:01 AM